| Literature DB >> 21561445 |
Ida Manna1, Antonio Gambardella, Amedeo Bianchi, Pasquale Striano, Rossana Tozzi, Umberto Aguglia, Francesca Beccaria, Paolo Benna, Roberto Campostrini, Maria P Canevini, Francesca Condino, Christine Durisotti, Maurizio Elia, Anna T Giallonardo, Alfonso Iudice, Angelo Labate, Angela La Neve, Roberto Michelucci, Gian C Muscas, Roberta Paravidino, Gaetano Zaccara, Claudio Zucca, Federico Zara, Emilio Perucca.
Abstract
A splice site variation (c.603-91G>A or rs3812718) in the SCN1A gene has been claimed to influence efficacy and dose requirements of carbamazepine and phenytoin. We investigated the relationship between c.603-91G>A polymorphism and response to antiepileptic drugs (AEDs) in 482 patients with drug-resistant and 401 patients with drug-responsive focal epilepsy. Most commonly used AEDs were carbamazepine and oxcarbazepine. The distribution of c.603-91G>A genotypes was similar among drug-resistant and drug-responsive subjects, both in the entire population and in the groups treated with carbamazepine or oxcarbazepine. There was no association between the c.603-91G>A genotype and dosages of carbamazepine or oxcarbazepine. These findings rule out a major role of the SCN1A polymorphism as a determinant of AED response. Wiley Periodicals, Inc.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21561445 DOI： 10.1111/j.1528-1167.2011.03097.x
Source DB: PubMed Journal: Epilepsia ISSN： 0013-9580 Impact factor: 5.864